Direct enterprise access to qualified analytical pipelines, pharmacological screening frameworks, and batch validation contracts.
In the contemporary CDMO landscape, global biotechnology and dietary conglomerate buyers encounter distinct operational, regulatory, and chemical barriers when transitioning from raw botanicals to clinical grade actives.
Unlike monolithic small-molecule synthesis, phytomedicines are exposed to seasonal, regional, and climate volatility. Unstandardized sourcing causes massive fluctuations in marker fractions, threatening bioequivalence.
Contracting preclinical pharmacology to one CRO while delegating pilot-scale extraction to an independent manufacturer generates technical silos, parameter drift, and compromised intellectual asset security.
Regulatory agencies such as the US FDA, EMA, and NMPA demand exhaustive evidence: LD50 toxicology, genotoxicity, reproducible stability profiling, and fully traceable origin footprints from commercial suppliers.
MedGence (Yineng Pharma) resolves procurement bottlenecks by unifying academic phytochemical discovery with modern cGMP manufacturing facilities under an entrusted, airtight confidentiality umbrella.
Systematic screening of active botanical components (alkaloids, polyphenols, polysaccharides, saponins) across distinct ecological origins and seasonal harvest windows.
Developing validated analytical assays via HPLC, HPTLC, and GC alongside high-yield extraction, supercritical purification, and crystalline refinement engineering.
Execution of GLP-compliant safety profiles: acute oral LD50, genotoxicity (Ames test), cellular in vitro assays, robust in vivo animal models, and Phase I–IV clinical studies.
Seamless transfer from pilot plants to commercial supply lines for bulk concentrated extracts, fine powders, volatile essential oils, tablets, capsules, and oral solutions.
Backing your pharmaceutical supply chain with decade-long empirical data and clinical registrations across major academic and hospital ecosystems.
Integrating artificial intelligence molecular mapping, continuous automated flow extraction, and nano-encapsulation to revolutionize active ingredient delivery.
Algorithmic satellite climate correlation predicting marker density across Asian microclimates for maximized active compound yields prior to physical harvest.
Next-generation closed-loop solvent-free extraction preserving thermosensitive terpene rings and polar phenolic molecules without toxic residual artifacts.
Resolving the historical pitfall of low botanical intestinal absorption via phospholipid complexes and micellar micro-encapsulation architectures.
High-throughput metabolomics pairing LC-MS/MS fingerprinting with cellular transcriptomics for unequivocal mechanism-of-action validation.
A resilient international pharmaceutical supply chain requires harmonized alignment with regional pharmacopoeias, audit-ready facilities, and responsive localized technical representatives.
Full support for Botanical Drug Guidance requirements and NDI (New Dietary Ingredient) notifications. We furnish complete 90-day subchronic toxicity data, Ames genotoxicity clearances, and heavy metal specifications adhering to USP guidelines.
Well-established dossier pathways for Traditional Herbal Medicinal Products (THMPD) and novel food compliance. Chromatographic fingerprints are mapped against Ph. Eur. monographs with PAH and pesticide residues controlled below strict EU limits.
Deep foundational alignment with China NMPA standards, hospital preparation formulas, and Asian dietary health supplements. Decades of collaboration with national hospitals ensure immediate regulatory synergy.
Direct answers covering contract scope, intellectual property defense, analytical methodology, and pilot-to-commercial batch capabilities.
Traditional suppliers simply broker or crush raw botanicals without rigorous chemical consistency. MedGence acts as an integrated CRO/CDMO: we perform molecular screening, establish HPTLC/HPLC fingerprints, evaluate seasonal potency variation, execute in vitro/in vivo toxicity and efficacy protocols, and manage direct scale-up within cGMP-compliant pilot and commercial facilities.
We operate strictly under legally binding bilateral Non-Disclosure Agreements (NDAs). Proprietary extraction solvents, fraction cutoff points, and custom formula matrices are managed under secure digital batch logs where personnel access is strictly compartmentalized. We do not commercialize or resell client proprietary active processes.
Our technical laboratory deploys high-performance thin-layer chromatography (HPTLC) for qualitative authentic identification, high-performance liquid chromatography (HPLC with DAD/ELSD) for quantitative assaying, gas chromatography (GC-MS) for volatile terpenes and residual solvents, along with multi-batch chromatographic fingerprint overlays ensuring consistent inter-lot chemical profiles.
Yes. In addition to small-cohort pilot human trials for functional foods and dietary supplements, our clinical operations unit structures, coordinates, and monitors rigorous Phase I, Phase II, Phase III, and Phase IV clinical programs aligned with ICH GCP standards, providing the regulatory data packages needed for formal New Drug Applications (NDA).
For active pharmaceutical ingredients (APIs) and intermediate botanicals, we provide spray-dried extract powders, concentrated liquids, vacuum pastes, and high-purity essential oils. For finished client packaging, our CDMO facilities produce enteric-coated capsules, softgels, micro-tablets, effervescent granules, sachets, and oral glass ampoules/liquids.
Active phytochemical concentrations fluctuate significantly based on harvest timing (e.g., pre-flowering vs. post-senescence) and terroir. By systematically profiling raw material lots across distinct Chinese agricultural belts and calendar windows, we lock in high-yield raw materials, driving down commercial extraction cost per kilogram while protecting potency.
Submit inquiries directly to our lead engineering and procurement team for rapid quotation, pilot test protocols, or commercial supply agreements.
Connect directly with our analytical chemists and pilot process engineers. We evaluate your target compound, define assay parameters, and provide formal fee structures within 48 business hours.
